Provisional programme

Provisional programme

Sunday 6 March 2011

18.00-19.00	Buffet dinner
19.00-20.50	Short position statements
	Chairs:	Guy Goodwin, United Kingdom Philippe Cupers, Belgium

19.00	Welcome and introduction Guy Goodwin, United Kingdom
19.05	The current and future size and burden of brain disorders in Europe Hans-Ulrich Wittchen, Germany
19.20	Health economics of brain disorders in Europe Bengt Jönsson, Sweden
19.35	The current position of the Pharmaceutical Industry-1 Atul C. Pande, GSK
19.50	The current position of the Pharmaceutical Industry- 2 Anders G. Pedersen, Lundbeck
20.05	The current position of the Pharmaceutical Industry- 3 Jeffrey S. Nye, Johnson&Johnson
20.20	The current position of the European Union-1
20.35	The current position of the European Union-2 Philippe Cupers, EU DG Research, Innovation and Science
20.50-21.30	General discussion and scene-setting for tomorrow
21.30	Dessert and drinks

Monday 7 March 2011

08.30-10.30	The scientific dimension
	Chairs:	Patrice Boyer, France David Nutt, United Kingdom

08.30-08.35	Introduction David Nutt, United Kingdom
08.35	Rationalising the approach to drug discovery for brain disorders Sven Schellberg, Switzerland
08.50	Discussion
09.00	Rationalising barriers to clinical research Adam Cohen, The Netherlands
09.15	Discussion
09.25	Is there a role for academic networks? Celso Arango, Spain
09.40	Discussion
09.50	Sharing costs: Is the Innovative Medicines Initiative (IMI) a model for clinical development? Shitij Kapur, United Kingdom
10.05	Discussion
10.15	General discussion
10.30	Break

11.00-11.45	Regulatory challenges: past, present and future
	Chairs:	Christine Gispen-de Wied, EMA David Nutt, United Kingdom

11.00	Introduction Christine Gispen-de Wied, EMA
11.05	EMA responsibilities and possibilities Maria Isaac, EMA
11.20	Discussion
11.30	Optimising guidelines Barbara van Zwieten-Boot, EMA
11.45	Discussion

11.55-12.25	The NIH approach to discovering new treatments
	Chair:	Joseph Zohar, Israel

11.55	Introduction Joseph Zohar, Israel
12.00	The NIH approach to discovering new treatments Thomas R. Insel, USA
12.15	Discussion
12.25	Lunch

13.30-16.00	The future of CNS drug research in Europe
	Chairs:	Guy Goodwin, United Kingdom Thomas Lönngren, past-ED EMA
	Facilitator:	David Nutt, United Kingdom

13.30	General discussion and brainstorming of possible solutions
15.30	Agreeing the ways forward and future meetings
16.00	Closure of the meeting

Related pages / downloads